STAT+: Trump administration revisits policy to close Medicare drug price negotiation loophole

The Trump administration proposed a policy to prevent drugmakers from evading Medicare price negotiations by adding active ingredients to drugs. The policy aims to finalize the selection of 20 drugs and biologics for negotiation by February 1, 2027, with negotiated prices taking effect in 2029. Medicare typically waits 7 to 11 years after FDA approval before negotiating prices, with biologics requiring longer delays.